公开(公告)号：US20090264341A1

公开(公告)日：2009-10-22

申请号：US12496924

申请日：2009-07-02

Applicant: Sudershan Kumar Arora ,  Vandita Srivastava ,  Sameer Shankar Walunj

Inventor： Sudershan Kumar Arora ,  Vandita Srivastava ,  Sameer Shankar Walunj

IPC: A61K38/16 ,  C07K2/00

CPC classification number: A61K36/66 ,  Y02A50/39

Abstract: A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

公开(公告)号：US07491721B2

公开(公告)日：2009-02-17

申请号：US10844992

申请日：2004-05-12

Applicant: Sudershan Kumar Arora ,  Neelima Sinha ,  Rakesh Sinha ,  Ram Shankar Upadhyaya

Inventor： Sudershan Kumar Arora ,  Neelima Sinha ,  Rakesh Sinha ,  Ram Shankar Upadhyaya

IPC: A61K31/12 ,  A61K31/33 ,  A61K31/135 ,  A61K31/165 ,  A61K31/166

CPC classification number: A61K31/131 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/4965 ,  A61K45/06 ,  A61K2300/00

Abstract: An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.

Abstract translation: 描述了用于治疗结核病的抗分支杆菌组合物和组合物。 使用的化合物是式（I）的N-（3 - [[4-（3-三氟甲基苯基）哌嗪基]甲基] -2-甲基-5-苯基 - 吡咯基）-4-吡啶基甲酰胺或药学上可接受的无毒盐 和一种或多种一线抗结核药物。

公开(公告)号：US07232835B2

公开(公告)日：2007-06-19

申请号：US10537851

申请日：2002-12-10

Applicant: Anita Mehta ,  Arundutt Viswanatham Silamkoti ,  Bruhaspathy Miriyala ,  Sudershan Kumar Arora ,  Boju Srinivasulu ,  Bireshwar Mukherjee ,  Jang Bahadur Gupta

Inventor： Anita Mehta ,  Arundutt Viswanatham Silamkoti ,  Bruhaspathy Miriyala ,  Sudershan Kumar Arora ,  Boju Srinivasulu ,  Bireshwar Mukherjee ,  Jang Bahadur Gupta

IPC: A01N43/40 ,  A01N43/00 ,  A61K31/445 ,  A61K31/55 ,  C07D221/02

CPC classification number: C07D401/06 ,  C07D209/52 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14

Abstract: This invention relates to derivatives of 3,6-disubstituted azabicyclo compounds. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

Abstract translation: 本发明涉及3,6-二取代的氮杂二环化合物的衍生物。 本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。 本发明还涉及含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

公开(公告)号：US07601368B2

公开(公告)日：2009-10-13

申请号：US10931814

申请日：2004-09-01

Applicant: Sudershan Kumar Arora ,  Vandita Srivastava ,  Sameer Shankar Walunj

Inventor： Sudershan Kumar Arora ,  Vandita Srivastava ,  Sameer Shankar Walunj

IPC: A61K36/00

CPC classification number: A61K36/66 ,  Y02A50/39

Abstract: A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

Abstract translation: 描述了通过选择性方法从Argemone mexicana植物的叶和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物。 还描述了从茄科植物的叶子和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物，其具有以下一种或多种作用：免疫抑制，淋巴增殖抑制，细胞因子调节如IL-2抑制，IFN γ抑制或IL-10诱导; 角质形成细胞增殖抑制，角质溶解活性和小鼠耳肿胀试验（MEST）中的抑制活性。

公开(公告)号：US20150025080A1

公开(公告)日：2015-01-22

申请号：US14129687

申请日：2012-06-29

Applicant: Poonam Kaushik ,  Ram Thaimattam ,  Mohan Prasad ,  Sudershan Kumar Arora

Inventor： Poonam Kaushik ,  Ram Thaimattam ,  Mohan Prasad ,  Sudershan Kumar Arora

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention provides processes for the preparation of amorphous form of sitagliptin dihydrogen phosphate. It also provides a solid dispersion of sitagliptin dihydrogen phosphate, including in the amorphous form, and processes for its preparation.

Abstract translation: 本发明提供了制备西格列汀磷酸二氢盐的无定形形式的方法。 它还提供了西他列汀磷酸二氢钠的固体分散体，包括无定形形式，及其制备方法。

公开(公告)号：US20140065191A1

公开(公告)日：2014-03-06

申请号：US13762792

申请日：2013-02-08

Applicant: Neeta GUPTA ,  Simrata BEDI ,  Jyoti SRIVASTAVA ,  Vinod Kumar ARORA ,  Manisha PANDYA ,  Vyas M. SHINGATGERI ,  Jaiprakash Jaysingrao BHELONDE ,  Monika OBRAH ,  Sanjay Kumar SHARMA ,  Rajinder K. JALALI ,  Sudershan Kumar ARORA

Inventor： Neeta GUPTA ,  Simrata BEDI ,  Jyoti SRIVASTAVA ,  Vinod Kumar ARORA ,  Manisha PANDYA ,  Vyas M. SHINGATGERI ,  Jaiprakash Jaysingrao BHELONDE ,  Monika OBRAH ,  Sanjay Kumar SHARMA ,  Rajinder K. JALALI ,  Sudershan Kumar ARORA

IPC: A61K9/14 ,  A61K31/155 ,  A61K31/555

CPC classification number: A61K9/14 ,  A61K9/0014 ,  A61K31/155 ,  A61K31/555 ,  A61K31/635 ,  A61K33/38 ,  A61K2300/00

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract translation: 本发明涉及用于人类或动物的烧伤治疗和微生物感染的局部药物组合物。 药物组合物包含0.1％w / w至1.0％w / w的抗微生物药物，即磺胺嘧啶银和0.2％w / w防腐剂，即葡萄糖酸氯己定，其中磺胺嘧啶磺胺为纳米形式。

公开(公告)号：US20090270330A1

公开(公告)日：2009-10-29

申请号：US12497148

申请日：2009-07-02

Applicant: Sudershan Kumar ARORA ,  Vandita Srivastava ,  Sameer Shankar Walunj

Inventor： Sudershan Kumar ARORA ,  Vandita Srivastava ,  Sameer Shankar Walunj

IPC: A61K38/16 ,  A61P17/06

CPC classification number: A61K36/66 ,  Y02A50/39

Abstract: A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

Abstract translation: 描述了通过选择性方法从Argemone mexicana植物的叶和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物。 还描述了从茄科植物的叶子和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物，其具有以下一种或多种作用：免疫抑制，淋巴增殖抑制，细胞因子调节如IL-2抑制，IFN γ抑制或IL-10诱导; 角质形成细胞增殖抑制，角质溶解活性和小鼠耳肿胀试验（MEST）中的抑制活性。

公开(公告)号：US20140350252A1

公开(公告)日：2014-11-27

申请号：US13985157

申请日：2012-02-21

Applicant: Nitin Maheshwari ,  Roshan Ramesh Medhane ,  Mohan Prasd ,  Sudershan Kumar Arora

Inventor： Nitin Maheshwari ,  Roshan Ramesh Medhane ,  Mohan Prasd ,  Sudershan Kumar Arora

IPC: C07D403/06

CPC classification number: C07D403/06

Abstract: The present invention relates to an improved stereoselective process for the preparation of (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol intermediate compound. This intermediate compound is further used to prepare voriconazole—a triazole antifungal agent.

Abstract translation: 本发明涉及用于制备（2R，3S / 2S，3R）-3-（4-氯-5-氟嘧啶-6-基）-2-（2,4-二氟苯基）-1 - （1H-1,2,4-三唑-1-基）丁-2-醇中间体化合物。 该中间体化合物进一步用于制备伏立康唑 - 三唑抗真菌剂。

公开(公告)号：US20140343290A1

公开(公告)日：2014-11-20

申请号：US14235127

申请日：2012-07-25

Applicant: Rakesh Kumar Singh ,  Nagaraju Gottumukkala ,  Mahavir Singh Khanna ,  Rajesh Kumar Thaper ,  Mohan Prasad ,  Sudershan Kumar Arora

Inventor： Rakesh Kumar Singh ,  Nagaraju Gottumukkala ,  Mahavir Singh Khanna ,  Rajesh Kumar Thaper ,  Mohan Prasad ,  Sudershan Kumar Arora

IPC: C07D213/42

CPC classification number: C07D213/42

Abstract: The present invention relates to an improved process for the preparation of atazanavir bisulfate, an inhibitor of retroviral aspartate protease. The process of the present invention comprises conversion of 1,1-dimethylethyl[(2S,3R)-4-chloro-3-hydroxy-phenylbutan-2-yl]carbamate (Formula II) into 1-[4-(pyridine-2-yl)-phenyl]-4(S)-5 hydroxy-2-N-tert-butoxycarbonylamino-5(S)—N—(N-methoxycarbonyl-(L)-tert-leucyl)amino-6-phenyl-2-azahexane (Formula VII) without isolating intermediate compounds formed therein, followed by its subsequent conversion to atazanavir or its bisulfate salt.

Abstract translation: 本发明涉及一种制备逆转录病毒天冬氨酸蛋白酶抑制剂阿扎那韦硫酸氢盐的改进方法。 本发明的方法包括将[（2S，3R）-4-氯-3-羟基 - 苯基丁-2-基]氨基甲酸酯（式II）的1,1-二甲基乙基酯转化为1- [4-（吡啶-2 - 基） - 苯基] -4（S）-5-羟基-2-N-叔丁氧基羰基氨基-5（S）-N-（N-甲氧基羰基 - （L） - 叔 - 亮氨酰基）氨基-6-苯基-2 （式Ⅶ），而不分离其中形成的中间体化合物，随后转化成阿扎那韦或其硫酸氢盐。

公开(公告)号：US20090247545A1

公开(公告)日：2009-10-01

申请号：US11577083

申请日：2004-12-28

Applicant: Mukund Keshao Gurjar ,  Madhusudan Nagorao Deshmukh ,  Anita Mehta ,  Sudershan Kumar Arora ,  Ashok Rattan

Inventor： Mukund Keshao Gurjar ,  Madhusudan Nagorao Deshmukh ,  Anita Mehta ,  Sudershan Kumar Arora ,  Ashok Rattan

IPC: A61K31/496 ,  C07D413/10 ,  A61P31/04

CPC classification number: C07D263/20 ,  C07D413/10

Abstract: The present invention provides substituted oxazolidinone derivatives, which can be used as antimicrobial agents. Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacteria, such as, inter alia, multiply-resistant Staphylococci, Streptococci, Enterococci, Bacterioides spp., Clostridium spp., Mycobacterium spp. Bacillus spp., Corynebacterium spp. Heptoslreptacoccus spp. Listeria spp., Legionella spp., Haemophilus influenza, Moraxella, Eschericia faecalis, and Eschericia coli. Processes for the preparation of disclosed compounds, pharmaceutical compositions thereof, and method of treating microbial infection are provided.

Abstract translation: 本发明提供了可用作抗微生物剂的取代的恶唑烷酮衍生物。 所公开的化合物可用于治疗或预防由细菌引起的或由细菌引起的病症，例如多重耐药葡萄球菌，链球菌，肠球菌，细菌属，梭菌属，分枝杆菌属。 芽孢杆菌属，棒状杆菌属 肝细胞线粒体 利斯特氏菌属（Listeria spp。），军团菌属（Legionella spp。），嗜血杆菌流感，流感嗜血杆菌，大肠埃希氏菌和大肠埃希氏菌。 提供了制备所公开化合物的方法，其药物组合物，以及治疗微生物感染的方法。